drugset / Trial / NCT06707896
TCR1020-CD8 T Cells in KRAS-mutated Cancers
Phase 1
Withdrawn
University of Pennsylvania
Lustgarten Foundation · collabStand Up To Cancer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma or colorectal cancer will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Timeline
- Start
- 2025-06-01
- Primary completion
- 2029-02-01
- Completion
- 2044-02-01
Outcome
Outcome not reported
Stopped: “Administrative decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TCR1020-CD8 T cells | Cell therapy | 1e+08 cells | — |
| Subject | TCR1020-CD8 T cells | Cell therapy | 3e+08 cells | — |
| Subject | TCR1020-CD8 T cells | Cell therapy | 1e+09 cells | — |
| Subject | TCR1020-CD8 T cells | Cell therapy | 3e+09 cells | — |